JLL Partners and Bart Doedens team up to launch Renovo Health

Related Topics

JLL Partners (JLL) has entered into a partnership with Bart Doedens, a specialist in the biomedical industry, to form Renovo Health, which seeks to buy, build, and develop materials technologies to provide a platform for improved efficacy across a spectrum of medical and dental procedures while offering an opportunity for near-term expansion. 

Renovo Health will focus on partnering with existing best-in-class operators, leveraging its deep expertise and organisational capabilities to facilitate organic growth as well as through the development of complementary offerings, operational improvement initiatives, and strategic mergers and acquisitions. JLL Partners has initially committed USD100 million to capitalise Renovo Health and fund future acquisitions, with additional capital available to pursue its growth strategy.

 
“I am thrilled to partner with JLL to build Renovo Health into a preeminent platform that can fundamentally improve people’s lives,” says Doedens. “Every year, millions of people undergo procedures for both acute and chronic conditions in a wide range of therapeutic applications, for which utilising the right medical materials can ensure fast and fulsome recuperation. These products also support healthy living and proactive care by enabling targeted drug delivery, pain management, cosmetic treatments, and more. By bringing together management’s sector knowledge, JLL’s track record of building transformational healthcare businesses, and the wide breadth of materials technologies and solutions available in the current marketplace, Renovo Health is ideally positioned to lead the next phase of growth in the industry.”
 
With more than 30 years of experience in the biomedical industry, Doedens most recently served as CEO of Collagen Matrix, an innovative manufacturer of collagen and mineral based medical devices to support tissue repair. Doedens led all facets of the company’s strategic expansion and business development, and made significant investments to enhance its people, processes, and systems. Previously, Doedens served as President of Biomet 3i, a global leader in the manufacturing and marketing of surgical products, including those used in bone healing, biologics, and dental reconstruction. Prior to Biomet 3i, Doedens was Vice President of Sirona Dental Systems and President and CEO of Atlas Spine.
 
“We firmly believe underlying demographic and healthcare trends, coupled with the increasing sophistication and applications for materials technologies, provide a strong backdrop for this endeavour,” says JLL Managing Director, Dan Agroskin. “Bart has proven time and again to be an exceptional leader, with the industry expertise and strategic vision requisite to back and build a market leading platform that is defined by its commitment to quality, technical differentiation, innovation, comprehensive scale, and customer service.”